Texas A&M scientists have unlocked new potential for astatine-211, a rare and short-lived element, as a highly precise cancer-fighting isotope. Its alpha emissions destroy tumor cells while sparing ...

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers ...

Read here for insights on Lineage’s cell therapy pipeline, key partnerships, and 2026 catalysts. Learn why now may be the ...

Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) ...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026New preclinical data demonstrated SIL204’s ...

In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality ...

New research suggests that people taking GLP-1 therapy are less likely to die from colorectal cancer. Ozempic, the cancer ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...

Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...

Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative ...

AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were ...